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Abstract
Objective: To verify the performance of a new method for obtaining platelet-rich plasma, while avoiding contami-
nation of the sample during its processing.
Study Design: Twenty healthy patients were selected, from whom 21 ml of blood was e�tracted. �e then pro-
ceeded to study the platelets and growth factors in basal blood after centrifuging the sample by using a new closed 
system for obtaining platelet-rich plasma (PRP).
Results: After centrifuging the blood sample, double the amount of platelets as that found in basal blood was 
obtained. Of the four growth factors analyzed, only the factor similar to insulin (IG�) contained the same con-
centration after the centrifuge process. The platelet-derived growth factor (PDG�) and the vascular growth factor 
(VG�) were multiplied by si� with respect to the basal values and disproportionately increased the levels of the 
transforming growth factor β (TGF-β).
Conclusions: The new closed method for obtaining PRP, after avoiding contamination of the sample following its 
use, offers levels of platelet concentrate and growth factors necessary for regeneration.
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Introduction
Platelet activation induces degranulation of the alpha 
granules that contain growth factors. Of all the growth 
factors, those that are most involved in healing are the 
transforming growth factor β (TGF-β), the factor simi-
lar to insulin (IG�), the platelet-derived growth factor 
(PDG�) and the vascular growth factor (VG�).
Platelet-rich plasma enables obtaining a high concen-
tration of growth factors. Its clinical application trig-
gers acceleration in the healing of soft tissues and bone 
neoformation (1). Mar� (2) studied the effect of platelet 
concentrate on the cells of the periodontal ligament in 
vitro, observing an increase in cell division and the se-
cretory function.  Karl et al. (3) applied concentrates of 
PRP to bone cell cultures, obtaining an increase in the 
percentage of proliferation and cell migration.
In the scienti�c literature, there is a large debate about 
the systems for obtaining PRP, in terms of the platelet 
concentrate and the integrity of the platelets during the 
handling and processing (4,5).
The objective of this study was the analysis of the effective-
ness of a new closed method for obtaining platelet concen-
trate and growth factors, in which e�posure of the blood to 
the e�ternal environment is avoided and the platelets are 
maintained in tact until the moment they are used.
Material and Method
Obtaining and processing of the sample
Twenty healthy volunteer patients were selected, with 
an age ranging from 19 to 23 years old. A peripheral 
e�traction of blood was performed (cephalic vein). �or 
the puncture, the Multyfly 21 G system was used, which 
was connected to a 3mI9NC Monovette syringe (3.30 ml 
of Stardet® sodium citrate).  Aspiration was performed 
gradually, given that it is less traumatic and fewer cells 
are destroyed. After the e�tractions, the plastic stem 
on the syringe was broken and introduced with the cap 
pointing downwards in the inserts of the centrifuge.
The sample was processed in a Bayer® conventional 
laboratory centrifuge, making a �rst centrifuge with 
800g for a period of 2 minutes, in order to eliminate 
the heavier elements (red blood cells). Once this was ac-
complished, the samples were placed face down in the 
rack, �nding two clearly distinguished phases, a lower 
part of the tube with red blood cells and another, on top, 
with the plasma. The red phase was eliminated by con-
necting a Multyfly® device and the plasma was centri-
fuged at 500g for 8 minutes. Three distinct phases were 
obtained from this second centrifugation. The �rst con-
tained residual red blood cells and leukocytes; the sec-
ond phase consisted of plasma rich in concentration of 
platelets, and the third phase consisted of platelet-poor 
plasma.  The �rst phase was aspirated again in order to 
dispose of it, and the rest of the tube was decanted in 
order to be analyzed.
Count and determination
�or each patient, we performed a count of basal platelets 
in the entire blood using the analyzer Cell-Dyn 3500 and 
determined the growth factors (PDGF, TGF-β, VGF) by 
means of ELISA from the laboratory Bender MedSys-
tem® and the IG� was determined by an enzymatically 
ampli�ed chemiluminescent immunometric assay of 
the laboratory Diagnostic Products Corporation®. After 
the centrifuge, we analyzed the part rich in platelets, 
with the platelet count and determination of the same 
growth factors as that analyzed in all of the blood.
�e e�tracted 21 ml of blood from each volunteer, which 
was placed into 7 tubes, each one with 3 ml. Upon cen-
trifuge, we obtained a resultant tube which contained 
between 4 to 5 ml of PRP. The sample was doubly di-
luted, pouring out more blood serum in order to achieve 
a minimum volume in order to make counts without e�-
tracting a large volume of blood from the patient.  
The Student T test was used as a parametric test for the 
statistical analysis, obtaining statistic signi�cance for 
p<0.05 and the test of the ranges with the �ilco�on sign 
as non-parametric, in order to study the statistic signi�-
cance of the results.
Results 
By applying the Student-T test, we are able to af�rm that 
the changes in concentration were signi�cant p<0.001 
in all of the parameters studied except in the TGF-β, in 
which it is not clearly signi�cant due to the high typi-
cal deviation. After contrasting the ranges with the �il-
co�on sign for matching data, we learned that from the 
20 samples in which the concentration of platelets was 
measured, it increased in 18 samples and decreased in 
only 2 samples (p<0.001). �ith respect to the concentra-
tion of the growth factors, there was an increase in IG� 
in only 8 samples, whereas the concentration decreased 
in the other 12 samples (p<0.05). The concentration of 
TGF-β increased in 13 samples, remained the same in 
one of them and decreased in the rest (p<0.001). In the 
20 samples, there was an increase in PDG� (p<0.001) 
and in VG� (p<0.001).
Platelet count 
The values obtained for basal platelets were within the 
normal values, with a minimum of 94,000 and a ma�i-
mum of 293,000/mm³.  The average platelet count was 
185,000/mm³, with a standard deviation of 43, which in-
dicates a very homogeneous sample. After centrifuging 
the samples, we observed an increase of appro�imately 
double in the count of concentrated platelets, given that 
the average was 354.71, with a standard deviation of 
128.8. 
Count of growth factors 
�or the same samples, the average concentration in ba-
sal blood of IG� was analyzed, which was 173.48, with a 
standard deviation of 48.57, of TGF-β equal to 22.33 and 
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Table 1. Values, in each one of the samples, of platelets per cubic millimeter of blood multiplied by 1000 
(PLT-1; in basal blood and PLT-2; in concentrate). Count of the basal growth factors (IGF-1, TGFβ-1, 
PDGF-1, VGF-1). Count of the concentrated growth factors (IGF-2, TGFβ-2, PDGF-2, VGF-2) in each 
one of the 20 samples.
 
PATIENT 
PLT-1 
/PLT-2 
(10X3/MM3) 
IGF-1 
/IGF-2 
(ng/ml) 
TGFȕ-1 
/TGFȕ-2 
(ng/ml) 
PDGF-1 
/PDGF-2 
(pg/ml) 
VGF-1 
/VGF-2 
(pg/ml) 
1 179 / 266 252 / 256 29.7 / 310.7 486 / 3204 22.4 / 227.6 
2 152 / 332 126 / 122 42.7 / 3.8 454 / 3435 80.1 / 176.3 
3 204 / 384 179 / 162 12 / 360 453 / 2646 147.4 / 320.3 
4 293 / 451 119 / 122 13,6 / 0,1 746 / 3657 1409.1 / 1592.2 
5 173 / 127 127 / 142 43.5 / 0.1 913 / 3452 102.6 / 237.2 
6 182 / 271 214 / 220 0.1 / 0.1 344 / 3419 80.1 / 250 
7 143 / 431 171 / 132 36.8 / 0.1 374 / 3378 67.3 / 359.4 
8 132 / 280 189 / 174 0.1 / 32.7 307 / 3035 3.2 / 121.8 
9 157 / 296 283 / 275 1.6 / 296.5 311 / 3110 3.2 / 35.3 
10 212 / 343 237 / 233 59.9 / 341 1461 / 3613 86.5 / 214.7 
11 163 / 147 132 / 131 0.5 / 53.2 1109 / 2466 16 / 86.5 
12 139 / 506 174 / 181 0.5 / 63.6 366 / 3076 28.8 / 691.4 
13 142 / 282 117 / 102 42.7 / 309.6 709 / 3400 25.6 / 484.4 
14 205 / 612 117 / 127 12.5 / 308.8 219 / 3347 35.3 / 335.9 
15 135 / 342 133 / 124 27.6 / 314.1 442 / 3277 32.1 / 402.3 
16 179 / 233 96,4 / 120 18 / 231.5 155 / 3270 125 / 429.7 
17 221 / 490 180 / 145 0.1 / 360 548 / 3439 76.9 / 507.8 
18 218 / 282 183 / 176 22.2 / 10.4 334 / 3165 64.1 / 359.4 
19 232 / 534 111 / 101 10.4 / 79.5 805 / 4000 70.5 / 410.2 
20 214 / 683 223 / 265 37.7 / 1102 494 / 4000 99.4 / 843.8 
Med Oral Patol Oral Cir Bucal. 2011 Jul 1;16 (4):e614-8.                                                                                                                                                         Growth factors and platelet-rich plasma
e617
standard deviation of 29.23. The PDG� was de 698.20, 
with a standard deviation of 487.26, and the average 
concentration for VG� was 164.12, with a standard de-
viation of 287.04.
Of the four growth factors analyzed, all of them were 
concentrated e�cept the IG�, which was to be e�pected 
given that the platelets are not their storage place. Thus, 
the values obtained are equal or less than the basal val-
ues, with an average value of 166.73 and a standard de-
viation of 49.97.
In the case of PDG� and VG�, the average concentrated 
values were si� times higher than the basal values. The 
average of the PDG� reached 3181.52, with a standard 
deviation of 565.17. �or VG�, the average was 423.38 
and a standard deviation of 333.16. And in determining 
the TGF-β, the average was 512 times higher than in the 
basal states, due to the fact that there was a large range 
in the e�treme values, from 0.10 to 1102ng/ml, with a 
standard deviation of 201.3 (Table 1).
Discussion 
One of the most debated applications for platelet-rich 
plasma has been bone regeneration. In this regard, 
Cheng et al. (6), as other authors have discussed, arrive 
at the conclusion that PRP combined with stem cells 
form a composite that is capable of improving bone re-
generation in critical defects generated in rabbits. �ith 
these same criteria, Nair et al. (7) arrive at the same 
conclusion with the e�ception of including a biomate-
rial such as hydro�yapatite in the mi�ture. Pieri et al. 
(8) obtain a higher percentage of bone formation with a 
mi�ture of stem cells and PRP in alveolar defects pro-
duced in the mandibles of mini-pigs.
In 2009, Plachokova et al. (9) carried out a systematic 
review in order to see the effect of PRP on bone regen-
eration in dentistry and arrive at the conclusion that it 
is useful in sinus lifts and in periodontal defects, con-
tradicting the conclusions that it had obtained in 2006. 
In another study by Plachokova et al. (10) in 2009, they 
concluded that PRP does not present signi�cant advan-
tages in laboratory animals such as rats. However, hu-
man PRP in combination with biomaterials aid the heal-
ing of bone grafts. 
There are also other studies that shed light on the pos-
sible secondary effects that may appear due to the in-
discriminate use of plasma with platelets, offering a 
perspective that differs from the majority of articles 
published on the topic (11,12). 
In our study, as already mentioned, the concentrates 
were diluted in order to have a suf�cient sample for 
determining the proteins, which is why our results and 
determinations, which are by unit of volume, are half of 
what would have been obtained if the correct amount 
of blood serum had been taken in order to be used in 
regeneration.  The amount of blood serum for having a 
suf�cient volume of concentrate would be 10 ml, given 
that the analyzer Cell Dyn needs a minimum volume of 
sample in order to determine the number of platelets, as 
well as for determining the growth factors. This was the 
justi�cation for diluting the sample.
The average of the concentration of platelets obtained 
was double the count in peripheral blood, which result-
ed in a poorer result than that obtained with other meth-
ods that were studied (13). This analysis was carried out 
with the absolute values in the samples taken, which, as 
aforementioned, were diluted. This data may appear to 
be discouraging with respect to the other methods, given 
that many of them quadrupled the number of platelets.
The concentration of IG� is practically the same in the 
concentrates as in the basal samples. The e�planation 
for this result is probably that the platelets are not a de-
posit of IG�, and no matter how much they are concen-
trated, this procedure will not increase their amount. 
The average of the results in the concentration of TGF-β 
is 521 times higher than that obtained by other authors 
when measuring the effectiveness of other methods (14). 
One of the reasons that such high values are obtained 
may be due to the e�treme values that came out in the 
samples and that deviated the average (11,000 ng/ml), 
but even when those values are eliminated, it continues 
to be eight times higher than the basal value. This can be 
e�plained by the early state of activation of the platelets, 
which has prevented the deposits of such proteins from 
being released. Our results are similar, and in any case, 
better than those obtained in other studies. �e may con-
sider that, although the platelet concentration obtained 
is not the same as with other systems, a greater integrity 
of the platelets is maintained in our study, which ena-
bles the TG� deposits that are in the alpha granules to 
be kept intact until the end, without losing their content, 
being able to be released when they are used. The PDG� 
and the VG� were concentrated si� times more than in 
the peripheral blood, which improves the results or at 
least matches those presented by other authors such as 
Hu Z et al. (15).
The study conducted by Anitua (16) analyzes a sample 
that is almost identical to ours.  It relates the concentrate 
of platelets with obtaining growth factors, concluding 
that there is variability in the concentration of VG� in 
different individuals, as also con�rmed by our results. 
They are able to focus on the average, but they also re-
port very different values, both e�cessive as well as a 
lack of concentration of platelets. The IG� concentra-
tion is totally independent from the number of platelets, 
given that their deposit in the platelets is minimal. The 
concentration of the other two growth factors ends up 
being between 2.5 and 3 times, whereas with our sys-
tem, it varies between 6 times for PDG� and 8 for TG�, 
which improves the aforementioned results.
The four protein counts obtained using our method have 
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achieved the results of other systems, despite the con-
centration of platelets being less in the majority of the 
systems, given that it is double and not quadruple. This 
caused us to consider that what was important was not 
the number of platelets, but the condition of these plate-
lets and their function in order to be used if needed. It is 
logical that if the processing of the sample damages or 
activates the platelets, the content of its granules would 
be released prematurely, and as a consequence, would 
be lost before being used.
The study by Mazzucco et al. (17) in 2009 further sup-
ports this hypothesis.  It analyzes four different methods 
for obtaining platelet-rich plasma. As has been demon-
strated, the different methods have distinct centrifuga-
tion systems in terms of centrifugal strength, which 
makes us think that it is not a determining factor for 
concentrating the platelets. They also use different anti-
coagulants and geli�cation methods. Despite the dif-
ferent methodologies, all of the systems achieve a good 
concentration of platelets, but it is demonstrated that 
there is no direct relationship between the amount of 
platelets and the growth factor concentration.  The con-
clusion of the author is that the handling of the samples 
causes damage to the platelets, such that they activate 
and release their content. This causes the clinical result 
to depend on the system used for obtaining the PRP.
The values that we obtained lead us to think that had 
the sample not been diluted, the results would have been 
better. In any case, the concentration of growth factors 
obtained is comparable to any other system, which 
would make it apt for being used in regeneration.
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